AAvec would overcome the critical issue of the short half-life of the enzyme to provide a “one shot” therapeutic for SLE and ANCA-vasculitis through continuous delivery of DNase I. AAvec technology has already been used successfully to treat blindness, clotting disorders, and neuromuscular disease in humans (102). This evidence concerns the gene DNASE1L3 and systemic lupus erythematosus.